OcuNexus Therapeutics Stock

ocunexus.comHealthcareFounded: 1900Funding to Date: $144.36MM

Ocunexus Therapeutics is a biotechnology company focused on inflammasome modulation for treatment of Dry Age-related Macular Degeneration and Diabetic Retinopathy.

Register for Details

For more details on financing and valuation for OcuNexus Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for OcuNexus Therapeutics.

Register Today

Team

Management Team

David Pool
Chief Financial Officer
Bradford Duft JD
Co-Founder, President & Board Member
Brian Levy
Chief Executive Officer
Anthony Phillips Ph.D
Medical & Pre-Clinical Consultant
Tracey Sunderland
Chief Operating Officer
Colin Green Ph.D
Scientific Co-Founder & Advisor
David Becker Ph.D
Scientific Co-Founder

Board Members

Howard Greene
Geoffrey Brooke MD
GBS Venture Partners
Bradford Duft JD
Inna Eitan
RusnanoMedInvest
James Blair Ph.D
Domain Associates
James Mervis JD
Mikhail Getman Ph.D
RusnanoMedInvest
Rajiv Shukla
Frank Spurway

Other companies like OcuNexus Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$327.39MM
Sector
 
 
Sector
Last Round Est. Valuation
$500MM